MUMBAI (TIP): Indian generic drugmaker Ranbaxy Laboratories said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid programme. The company, which has agreed to be acquired by rival Sun Pharmaceutical Industries, said it had received a civil investigative demand (CID) from the US Department of Justice (DOJ) and that it would fully cooperate with the investigation. “The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation,” the company said in a statement. Last year, Ranbaxy pleaded guilty to felony charges related to drug safety.
Related Articles
US warns China to avoid tensions in international airspace
WASHINGTON (TIP): The United States warned China on Thursday against risking tensions in international airspace after Japan accused Beijing of “dangerous maneuvers” above disputed areas of the East China Sea. State department spokeswoman Jen Psaki […]
US might take the hard option in Afghanistan
KABUL (TIP): The US official policy on supporting a “peace process” in Afghanistan may change. In remarks at Canberra, US defence secretary James Mattis gave clear indication that the US may not give Taliban the space for a political “solution” in Afghanistan. The […]
Border Patrol gets new guidelines for immigrant detentions
DALLAS, TX (TIP): The U.S. Customs and Border Protection has issued a sweeping new set of standards for handling immigrant detainees, following a year of heightened criticism over agency practices. The 31-page document—the first of […]
Be the first to comment